| Literature DB >> 32353347 |
Qifang Bi1, Yongsheng Wu2, Shujiang Mei3, Chenfei Ye4, Xuan Zou5, Zhen Zhang2, Xiaojian Liu2, Lan Wei2, Shaun A Truelove6, Tong Zhang7, Wei Gao3, Cong Cheng3, Xiujuan Tang3, Xiaoliang Wu3, Yu Wu8, Binbin Sun9, Suli Huang10, Yu Sun7, Juncen Zhang7, Ting Ma11, Justin Lessler12, Tiejian Feng13.
Abstract
BACKGROUND: Rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, prompted heightened surveillance in Shenzhen, China. The resulting data provide a rare opportunity to measure key metrics of disease course, transmission, and the impact of control measures.Entities:
Mesh:
Year: 2020 PMID: 32353347 PMCID: PMC7185944 DOI: 10.1016/S1473-3099(20)30287-5
Source DB: PubMed Journal: Lancet Infect Dis ISSN: 1473-3099 Impact factor: 25.071
Demographic and clinical characteristics of cases by contact-based versus symptom-based surveillance
| Female | 63 (72%) | 131 (45%) | 10 (83%) | 204 (52%) | <0·0001 |
| Male | 24 (28%) | 161 (55%) | 2 (17%) | 187 (48%) | .. |
| 0–9 years | 13 (15%) | 6 (2%) | 1 (8%) | 20 (5%) | <0·0001 |
| 10–19 years | 5 (6%) | 6 (2%) | 1 (8%) | 12 (3%) | .. |
| 20–29 years | 11 (13%) | 23 (8%) | 0 (0%) | 34 (9%) | .. |
| 30–39 years | 15 (17%) | 71 (24%) | 1 (8%) | 87 (22%) | .. |
| 40–49 years | 9 (10%) | 49 (17%) | 2 (17%) | 60 (15%) | .. |
| 50–59 years | 10 (12%) | 63 (22%) | 1 (8%) | 74 (19%) | .. |
| 60–69 years | 20 (23%) | 60 (21%) | 6 (50%) | 86 (22%) | .. |
| ≥70 years | 4 (5%) | 14 (5%) | 0 (0%) | 18 (5%) | .. |
| Mild | 18 (21%) | 82 (28%) | 2 (17%) | 102 (26%) | 0·03 |
| Moderate | 66 (76%) | 180 (62%) | 8 (67%) | 254 (65%) | .. |
| Severe | 3 (3%) | 30 (10%) | 2 (17%) | 35 (9%) | .. |
| No | 17 (20%) | 8 (3%) | 0 (0%) | 25 (6%) | <0·0001 |
| Yes | 70 (80%) | 284 (97%) | 12 (100%) | 366 (94%) | .. |
| No | 25 (29%) | 34 (12%) | 2 (17%) | 61 (16%) | 0·0002 |
| Yes | 62 (71%) | 258 (88%) | 10 (83%) | 330 (84%) | .. |
Association of clinical and demographic factors with mode of detection and severity at initial assessment
| Univariate regression | Multivariate regression | Univariate regression | Multivariate regression | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | 2·5% | 97·5% | OR | 2·5% | 97·5% | OR | 2·5% | 97·5% | OR | 2·5% | 97·5% | |
| Female | Ref | .. | .. | Ref | .. | .. | Ref | .. | .. | Ref | .. | .. |
| Male | 3·23 | 1·93 | 5·53 | 3·06 | 1·77 | 5·44 | 1·30 | 0·82 | 2·07 | 1·37 | 0·85 | 2·22 |
| 0–9 years | 0·07 | 0·02 | 0·23 | 0·08 | 0·02 | 0·25 | 0·88 | 0·30 | 2·77 | 0·67 | 0·22 | 2·23 |
| 10–19 years | 0·19 | 0·05 | 0·77 | 0·17 | 0·04 | 0·76 | 1·08 | 0·28 | 5·27 | 0·88 | 0·22 | 4·40 |
| 20–29 years | 0·33 | 0·12 | 0·89 | 0·37 | 0·13 | 1·02 | 0·65 | 0·28 | 1·56 | 0·61 | 0·26 | 1·49 |
| 30–39 years | 0·75 | 0·31 | 1·77 | 0·8 | 0·32 | 1·93 | 1·17 | 0·58 | 2·37 | 1·15 | 0·57 | 2·33 |
| 40–49 years | 0·86 | 0·32 | 2·33 | 0·79 | 0·29 | 2·19 | 1·27 | 0·58 | 2·83 | 1·21 | 0·55 | 2·72 |
| 50–59 years | Ref | .. | .. | Ref | .. | .. | Ref | .. | .. | Ref | .. | .. |
| 60–69 years | 0·48 | 0·2 | 1·08 | 0·44 | 0·18 | 1·04 | 1·50 | 0·72 | 3·16 | 1·43 | 0·68 | 3·03 |
| ≥70 years | 0·56 | 0·16 | 2·25 | 0·45 | 0·12 | 1·89 | 1·41 | 0·45 | 5·43 | 1·28 | 0·40 | 4·96 |
| Mild | Ref | .. | .. | Ref | .. | .. | .. | .. | .. | .. | .. | .. |
| Moderate | 0·6 | 0·33 | 1·05 | 0·51 | 0·26 | 0·94 | .. | .. | .. | .. | .. | .. |
| Severe | 2·2 | 0·68 | 9·84 | 1·51 | 0·42 | 7·23 | .. | .. | .. | .. | .. | .. |
| No | Ref | .. | .. | .. | .. | .. | Ref | .. | .. | .. | .. | .. |
| Yes | 3·06 | 1·69 | 5·49 | .. | .. | .. | 0·94 | 0·49 | 1·75 | .. | .. | .. |
| No | Ref | .. | .. | .. | .. | .. | Ref | .. | .. | .. | .. | .. |
| Yes | 8·62 | 3·68 | 21·89 | .. | .. | .. | 0·51 | 0·15 | 1·39 | 0·55 | 0·29 | 1·01 |
| Contact-based | .. | .. | .. | .. | .. | .. | Ref | .. | .. | .. | .. | .. |
| Symptom-based | .. | .. | .. | .. | .. | .. | 0·67 | 0·37 | 1·17 | .. | .. | .. |
OR=odds ratio.
Figure 1Incubation period and serial interval of COVID-19
(A) Proportion of cases who developed symptoms of coronavirus disease 2019 (COVID-19) by days after infection (ie, the cumulative distribution function of the incubation period). (B) Proportion of cases infected by an index case who developed symptoms by a given number of days after the day of symptom onset of the index case (ie, the cumulative distribution function of the serial interval). The maximum-likelihood estimates for the parametric distribution of the cumulative distribution function are shown, along with 1000 parametric bootstrap estimates of the cumulative distribution function. The median incubation period of COVID-19 is estimated to be 4·8 days (95% CI 4·2–5·4). 5% of cases who develop symptoms will do so by 1·6 days (95% CI 1·3–2·0) after infection, and 95% by 14·0 days (12·2–15·9). We estimated that the median serial interval of COVID-19 is 5·4 days (95% CI 4·4–6·5). 5% of infected cases who develop symptoms will do so by 1·3 days (95% CI 0·9–1·9) after symptom onset of the index case, and 95% by 14·3 days (11·1–17·6).
Figure 2Time between symptom onset and SARS-CoV-2 confirmation (A), admission to hospital (B), and isolation among cases (C) detected by contact-based and symptom-based surveillance
The maximum-likelihood estimates for the parametric distribution of the cumulative distribution function are shown, along with 1000 parametric bootstrap estimates of the cumulative distribution function. Panel A shows estimates of the proportion of cases who are confirmed by RT-PCR, according to the number of days after symptom onset. We estimated that 50% of cases detected through symptom-based surveillance were confirmed by RT-PCR within 4·6 days (95% CI 4·2–5·0) after symptom onset, and 95% were confirmed by RT-PCR within 12·7 days (11·5–13·8) after symptom onset. Contact-based surveillance reduced the days from symptom onset to RT-PCR confirmation to 2·9 days (95% CI 2·4–3·4) in 50% of cases and to 6·6 days (5·3–8·0) in 95% of cases. Panel B shows estimates of the proportion of cases who were admitted to hospital, according to the number of days after symptom onset. We estimated that 50% of the cases detected through symptom-based surveillance were admitted to hospital by 3·4 days (95% CI 3·1–3·8) after symptom onset, and 95% by 12·4 days (10·9–13·8). Contact-based surveillance reduced the days from symptom onset to hospital admission to 2·1 days (95% CI 1·7–2·6) in 50% of cases, and 6·0 days (95% CI 4·5–7·5) in 95% of cases. Panel C shows estimates of the proportion of cases isolated, according to number of days after symptom onset. We estimated that 50% of cases detected through symptom-based surveillance were isolated by 3·4 days (95% CI 3·1–3·7) after symptom onset, and 95% by 12·2 days (95% CI 10·8–13·6). Contact-based surveillance reduced the days from symptom onset to isolation to 2·2 days (95% CI 1·7–2·6) in 50% of cases, and to 6·5 days (4·7–8·2) in 95% of cases.
Group-specific attack rates and risk factors for SAR-CoV-2 infection among close contacts
| Odds ratio | 2·5% | 97·5% | Odds ratio | 2·5% | 97·5% | ||||
|---|---|---|---|---|---|---|---|---|---|
| Female | 558 | 58 | 10·4% (8·1–13·2) | Ref | .. | .. | .. | .. | .. |
| Male | 486 | 26 | 5·3% (3·7–7·7) | 0·43 | 0·21 | 0·86 | .. | .. | .. |
| 0–9 years | 148 | 11 | 7·4% (4·2–12·8) | 2·33 | 0·38 | 14·05 | .. | .. | .. |
| 10–19 years | 85 | 6 | 7·1% (3·3–14·6) | 3·50 | 0·53 | 23·24 | .. | .. | .. |
| 20–29 years | 114 | 7 | 6·1% (3·0–12·1) | 4·91 | 0·74 | 32·64 | .. | .. | .. |
| 30–39 years | 268 | 16 | 6·0% (3·7–9·5) | 1·84 | 0·34 | 9·80 | .. | .. | .. |
| 40–49 years | 143 | 7 | 4·9% (2·4–9·8) | 3·46 | 0·55 | 21·92 | .. | .. | .. |
| 50–59 years | 110 | 10 | 9·1% (5·0–15·9) | Ref | .. | .. | .. | .. | .. |
| 60–69 years | 130 | 20 | 15·4% (10·2–22·6) | 5·68 | 1·01 | 32·09 | .. | .. | .. |
| ≥70 years | 72 | 7 | 9·7% (4·8–18·7) | 4·26 | 0·64 | 28·44 | .. | .. | .. |
| No | 456 | 4 | 0·9% (0·3–2·2) | Ref | .. | .. | Ref | .. | .. |
| Yes | 686 | 77 | 11·2% (9·1–13·8) | 15·10 | 3·69 | 61·69 | 6·27 | 1·49 | 26·33 |
| No | 824 | 63 | 7·6% (6·0–9·7) | Ref | .. | .. | Ref | .. | .. |
| Yes | 318 | 18 | 5·7% (3·6–8·8) | 9·13 | 1·85 | 45·08 | 7·06 | 1·43 | 34·91 |
| No | 435 | 20 | 4·6% (3·0–7·0) | Ref | .. | .. | Ref | .. | .. |
| Yes | 707 | 61 | 8·6% (6·8–10·9) | 23·01 | 2·51 | 211·2 | 7·13 | 0·73 | 69·32 |
| Rare | 230 | 1 | 0·4% (0·02–2·4) | <0·0001 | 0 | Inf | .. | .. | .. |
| Moderate | 305 | 9 | 3·0% (1·6–5·5) | Ref | .. | .. | .. | .. | .. |
| Often | 555 | 71 | 12·8% (10·3–15·8) | 8·8 | 2·58 | 30·06 | .. | .. | .. |
SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. Inf=infinity.
15 confirmed close contacts were excluded from this analysis because contact tracing reports for the negative close contacts in the same clusters were missing. Close contacts with missing data on sex, age, contact types, or contact frequency not shown.
Figure 3Attack rate among close contacts, baseline severity, and proportion of cases without fever at initial assessment by age group
*Proportion of close contacts for attack rate; proportion of all cases for those with severe symptoms or no fever at initial assessment.